Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Gross Profit: 2020-2024

Historic Gross Profit for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $206.5 million.

  • Oncology Institute's Gross Profit rose 3169.98% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.1 million, marking a year-over-year increase of 10942.12%. This contributed to the annual value of $206.5 million for FY2024, which is 4420.41% up from last year.
  • According to the latest figures from FY2024, Oncology Institute's Gross Profit is $206.5 million, which was up 4420.41% from $143.2 million recorded in FY2023.
  • Oncology Institute's 5-year Gross Profit high stood at $206.5 million for FY2024, and its period low was $91.8 million during FY2020.
  • Moreover, its 5-year median value for Gross Profit was $117.7 million (2022), whereas its average is $132.6 million.
  • Its Gross Profit has fluctuated over the past 5 years, first skyrocketed by 1289.56% in 2021, then soared by 4420.41% in 2024.
  • Oncology Institute's Gross Profit (Annual) stood at $91.8 million in 2020, then grew by 12.9% to $103.6 million in 2021, then rose by 13.63% to $117.7 million in 2022, then rose by 21.66% to $143.2 million in 2023, then soared by 44.2% to $206.5 million in 2024.
  • Its last three reported values are $206.5 million in FY2024, $143.2 million for FY2023, and $117.7 million during FY2022.